• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.

作者信息

Moghadam Parna, Tancrede Emmanuelle, Bouaziz Jean-David, Kallout Julien, Bedane Christophe, Begon Edouard, Bourgault-Villada Isabelle, Calugareanu Andreea, Dereure Olivier, Jendoubi Fatma, Pham-Ledard Anne, Ingen-Housz-Oro Saskia, Picard-Dahan Catherine, Viguier Manuelle, Mahevas Thibault, Jachiet Marie, Charvet Estelle, Cassius Charles, Alexandre Marina, Lepelletier Clémence

机构信息

Dermatology Department, Saint-Louis Hospital, Paris, France.

出版信息

Br J Dermatol. 2023 Jul 17;189(2):244-246. doi: 10.1093/bjd/ljad136.

DOI:10.1093/bjd/ljad136
PMID:37155583
Abstract
摘要

相似文献

1
Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.度普利尤单抗治疗大疱性类天疱疮的疗效和安全性：一项对36例患者的回顾性多中心研究。
Br J Dermatol. 2023 Jul 17;189(2):244-246. doi: 10.1093/bjd/ljad136.
2
Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.度普利尤单抗治疗大疱性类天疱疮的长期治疗效果及安全性：一项多中心回顾性研究。
J Am Acad Dermatol. 2023 Aug;89(2):378-382. doi: 10.1016/j.jaad.2023.03.036. Epub 2023 Apr 26.
3
Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.度普利尤单抗治疗帕博利珠单抗诱导的大疱性类天疱疮：一例报告
Dermatol Ther. 2022 Aug;35(8):e15623. doi: 10.1111/dth.15623. Epub 2022 Jun 24.
4
Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.度普利尤单抗治疗严重大疱性类天疱疮的长期疗效和安全性：一项前瞻性队列研究。
Int Immunopharmacol. 2023 Dec;125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157. Epub 2023 Nov 3.
5
Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid.度普利尤单抗治疗顽固性大疱性类天疱疮104周的有效性和安全性。
Skin Res Technol. 2023 Oct;29(10):e13488. doi: 10.1111/srt.13488.
6
Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.评论：度普利尤单抗治疗中重度大疱性类天疱疮的疗效与安全性
Front Immunol. 2021 Nov 23;12:800609. doi: 10.3389/fimmu.2021.800609. eCollection 2021.
7
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.度普利尤单抗治疗中重度大疱性类天疱疮的疗效和安全性。
Front Immunol. 2021 Oct 14;12:738907. doi: 10.3389/fimmu.2021.738907. eCollection 2021.
8
Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.度普利尤单抗治疗纳武利尤单抗诱导的大疱性类天疱疮：一例病例报告及文献综述
Dermatol Online J. 2021 Sep 15;27(9). doi: 10.5070/D327955136.
9
Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.希卡姆与奥卡姆之争：特应性皮炎与大疱性类天疱疮或结节性类天疱疮？度普利尤单抗解决了这个问题。
Ital J Dermatol Venerol. 2024 Jun;159(3):361-363. doi: 10.23736/S2784-8671.24.07741-7. Epub 2024 May 2.
10
Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.度普利尤单抗联合低剂量全身类固醇治疗改善大疱性类天疱疮的疗效和安全性。
Dermatol Ther. 2022 Aug;35(8):e15648. doi: 10.1111/dth.15648. Epub 2022 Jul 1.

引用本文的文献

1
IgG autoantibodies in bullous pemphigoid induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes.大疱性类天疱疮中的IgG自身抗体在角质形成细胞中诱导致病性的依赖MyD88的促炎反应。
Nat Commun. 2025 Aug 6;16(1):7254. doi: 10.1038/s41467-025-62495-2.
2
Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.度普利尤单抗治疗特应性皮炎患者后发生的皮肤T细胞淋巴瘤：临床综述与建议
Am J Clin Dermatol. 2025 May 26. doi: 10.1007/s40257-025-00955-7.
3
Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis.
度普利尤单抗治疗中重度大疱性类天疱疮患者的疗效和安全性：一项系统评价和荟萃分析
An Bras Dermatol. 2025 May-Jun;100(3):429-438. doi: 10.1016/j.abd.2024.08.008. Epub 2025 Mar 29.
4
Bullous pemphigoid.大疱性类天疱疮
Nat Rev Dis Primers. 2025 Feb 20;11(1):12. doi: 10.1038/s41572-025-00595-5.
5
Successful Treatment of Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature.奥马珠单抗成功治疗免疫检查点抑制剂诱导的大疱性类天疱疮：病例报告及文献综述
Clin Cosmet Investig Dermatol. 2024 Dec 14;17:2865-2874. doi: 10.2147/CCID.S487711. eCollection 2024.
6
Use of dupilumab for recalcitrant bullous pemphigoid: A case report.度普利尤单抗用于治疗顽固性大疱性类天疱疮：一例报告。
SAGE Open Med Case Rep. 2024 Aug 22;12:2050313X241274855. doi: 10.1177/2050313X241274855. eCollection 2024.
7
Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study.度普利尤单抗治疗大疱性类天疱疮期间快速止痒可预测临床疗效：一项回顾性队列研究
Dermatology. 2024;240(5-6):694-701. doi: 10.1159/000540590. Epub 2024 Jul 29.
8
Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.度普利尤单抗通过抑制多种细胞类型的活性，有效且快速地治疗大疱性类天疱疮。
Front Immunol. 2023 Jul 27;14:1194088. doi: 10.3389/fimmu.2023.1194088. eCollection 2023.